...Lan Lan; Yuxin Lin; Binfeng Yu; Yin Wang; Hong Pan; Huijing Wang; Xiaowei Lou; Xiabing Lang; Qiankun Zhang; Lie Jin; Yi Yang; Liang Xiao; Jianghua Chen; Fei Han Introduction: Rituximab has been proven effective and safe in pediatric patients with frequently relapsing or steroid-dependent nephrotic...

... with significant adverse effects and a high relapse rate. Novel interventions, including targeting B cells with rituximab as well as treatment with adrenocorticotropic hormone (ACTH), are being investigated. Key Messages: The understanding of treatment targets and availability of new biomarkers has facilitated...

... is unclear, especially in light of the success of B-cell-directed therapy. Methods: Renal biopsies from 33 patients treated with cyclophosphamide (CYC; n = 17) or rituximab (RTX; n = 16) in the RTX in ANCA-associated vasculitis (RAVE) trial were classified according to the new ANCA GN classification. T...

...Dario Roccatello; Savino Sciascia; Daniela Rossi; Mirella Alpa; Carla Naretto; Massimo Radin; Antonella Barreca; Roberta Fenoglio; Simone Baldovino; Elisa Menegatti Background: A beneficial effect of rituximab (RTX) on focal segmental glomerulosclerosis (FSGS) in pediatric patients or in transplant...

... on electron microscopy. Although effective in children, corticosteroid treatment in adults is more variable and time to response can be prolonged. Data to support rituximab use in adults with corticosteroid-dependent or resistant minimal-change glomerulopathy are limited. Here, we describe the clinical course...

...Dario Roccatello; Savino Sciascia; Simone Baldovino; Daniela Rossi; Mirella Alpa; Carla Naretto; Debora Di Simone; Elisa Menegatti Background: In a prospective, single-center open study, we evaluated the very long-term effects of rituximab (RTX) administered to patients with severe mixed...

...Shivani Shah; Zdenka Hruskova; Marten Segelmark; Matthew D. Morgan; Jonathan Hogan; Steven K. Lee; Jessica Dale; Lorraine Harper; Vladimir Tesar; David R.W. Jayne; Duvuru Geetha Background/Aims: Rituximab and glucocorticoids are a non-inferior alternative to cyclophosphamide and glucocorticoid...

...Michael L. Spinner; Lyndsey J. Bowman; Timothy A. Horwedel; Rowena B. Delos Santos; Christina L. Klein; Daniel C. Brennan Background/Aims: Post-renal transplant recurrent glomerulonephritis (GN) contributes to allograft loss. Rituximab treatment has been used in a multidose strategy with variable...

... and other immunosuppressive agents exhibit an unfavorable adverse event spectrum. The aim of this review was to systematically summarize and analyze data from preexisting studies reporting the outcome of rituximab (RTX) treatment in these patients. Methods: Study data on adult patients with either steroid...

...Takahisa Kimata; Masafumi Hasui; Jiro Kino; Tetsuya Kitao; Sohsaku Yamanouchi; Shoji Tsuji; Kazunari Kaneko Background: Though rituximab (RTX) is effective for childhood steroid-dependent nephrotic syndrome (SDNS), an established regimen does not exist. The relapses tend to occur when...

... including cyclophosphamide were enrolled. All patients received rituximab as a rescue therapy and were followed for 30–54 months. Following rituximab administration, immunosuppressive drugs were rapidly tapered and no immunosuppressive maintenance therapy was given. Results: Significant decreases in levels...

...Paolo Cravedi; Maria Chiara Sghirlanzoni; Maddalena Marasà; Alessandra Salerno; Giuseppe Remuzzi; Piero Ruggenenti Background/Aims: First-line immunosuppression with the B-cell depleting antibody rituximab reduced proteinuria and induced remission of the disease in patients with nephrotic syndrome...